EUVIMEDEUVIMED entdecken
Multizentrische StudieStudienprotokoll

Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol

Hana Yoshida, Satoru Inoda, Hidenori Takahashi, Ryota Takahashi, Yuto Hashimoto, Hironori Takahashi, Hidetoshi Kawashima, Yasuo Yanagi

Graefe's Archive for Clinical and Experimental Ophthalmology · 2024

DOI: 10.1007/s00417-024-06577-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Hana Yoshida und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Intravitreal Injections, Wet Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the real-world 2-year treatment outcomes of intravitreal brolucizumab (IVBr) for neovascular age-related macular degeneration (nAMD). METHODS: This multicenter, prospective, and interventional study included 53 eyes treated with brolucizumab from October 2020 to August 2021 at 3 institutions. A modified treat-and-extend (TAE) regimen with predefined discontinuation criteria was used. The mTAE regimen was discontinued if patients responded positively and achieved a treatment interval of 16 weeks twice with no sign of recurrence. The number of patients discontinuing TAE and the visual and anatomic changes at 1 and 2 years after the first IVBr were evaluated. RESULTS: Thirty-eight eyes from 38 patients (71%) completed the 2-year observation period and 7 eyes from 7 patients experienced intraocular inflammation (IOI). Of these 38 patients, 18 (47%) could discontinue the TAE at a median [interquartile range] of 13.1 [12.9-16.8] months after the first IVBr. Best-corrected visual acuity, central subfield retinal thickness, and central choroidal thickness were significantly improved compared with baseline at both 1 and 2 years after the first IVBr (all P < 0.001). An extension study revealed a 1-year recurrence rate of 5.6% (standard deviation, 5.4%) after TAE discontinuation. CONCLUSIONS: While IOI is a concern with brolucizumab, careful observation allows discontinuing the TAE regimen in patients treated with IVBr. Moreover, brolucizumab may reduce the risk of recurrence after treatment interruption. TRIAL REGISTRATION NUMBER: UMIN Clinical Trials Registry ( http://www.umin.ac.jp/ ; R000050688 UMIN 000044374).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedIntravitreal InjectionsWet Macular DegenerationAgedAged, 80 and overFemaleHumansMaleFluorescein AngiographyFollow-Up StudiesFundus OculiProspective StudiesTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual Acuity

Stichwörter der Autor:innen

Age-related macular degenerationBrolucizumabModified treat-and-extend regimenVascular endothelial growth factor

Substanzen

Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedbrolucizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan.
  • Department of Ophthalmology, Sano City Hospital, Sano-shi, Tochigi, Japan.
  • Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0431, Japan. r1208is@jichi.ac.jp.
  • Department of Ophthalmology, Haga Japanese Red Cross Hospital, Mooka-shi, Tochigi, Japan.
  • Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan.
  • Retina Research Group, Duke-NUS Medical School, Singapore Eye Research Institute, Singapore Eye-ACP, National University of Singapore, 8 College Road, Singapore, 169857, Singapore.

Zitieren

APA

Yoshida, H., Inoda, S., Takahashi, H., Takahashi, R., Hashimoto, Y., Takahashi, H., Kawashima, H., & Yanagi, Y. (2024). Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06577-9

Vancouver

Yoshida H, Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Takahashi H, et al. Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06577-9

BibTeX
@article{Yoshida2024,
  author = {Yoshida, Hana and Inoda, Satoru and Takahashi, Hidenori and Takahashi, Ryota and Hashimoto, Yuto and Takahashi, Hironori and Kawashima, Hidetoshi and Yanagi, Yasuo},
  title = {Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2024},
  doi = {10.1007/s00417-024-06577-9}
}
Kostenlos starten →